WW International Aims for Free Cash Flow Positivity as GLP-1 Care Subscribers Surge
WW International (NASDAQ: WW) is forecasting a return to free cash flow positivity in the current year, driven by its strategic shift toward behavioral support and clinical services involving GLP-1 medications. The company has significantly reduced debt from $1.6 billion to approximately $465 million through restructuring efforts, cutting annual interest expenses nearly in half. Clinical subscribers for WW's Med+ service grew almost 56% year-over-year during the second quarter of 2026, with clinical revenue expected to represent 25%-30% of total revenue by this year—up from just 10% two years ago. The company also announced a guidance range of $620 million–$635 million in annual revenue and adjusted EBITDA between $105 million–$115 million for the same period. WW is increasing marketing spend to raise awareness around its GLP-1 offerings while expanding partnerships with entities like Sam's Club and LillyDirect. The company emphasizes a holistic approach, combining telehealth access, behavioral support programs, and virtual workshops as part of its broader strategy.
Tickers: $WW
Topics: debt_reduction free_cash_flow GLP-1_growth restructuring